Gilead Sciences, Inc. announced today that the China Drug Administration (CDA) has approved Epclusa? (sofosbuvir 400 mg/velpatasvir 200 mg) for the treatment of adults with genotype 2-6 chronic hepatitis C virus (HCV) in……
The European Medicines Agency (EMA) has approved LYNPARZA? (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian ……
AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a ……
The U.S. Food and Drug Administration today (May 22, 2028) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 20 years and older. This is the first FDA approval of a ……
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Verzenio? (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy f……
The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormon……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
